Clinical Trial: An open-label, multicenter, exploratory Phase II clinical study of the efficacy and safety of TR115 in patients with advanced solid tumors with ARID1A mutations (China)

China, Sept. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An open-label, multicenter, exploratory Phase II clinical study of the efficacy and safety of TR115 in patients with advanced solid tumors with ARID1A mutations'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600132021

Registration Time: 2026/09/09

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341659

Published by HT Digital Content Services with permission from Health Daily Digest....